 

West Pharmaceutical Services, Inc. reported strong financial results for the third quarter of 2020, with organic sales growth of approximately 18%. The company's Contract Manufacturing business experienced growth of 17.9% in gross profit margin, driven by improved efficiencies and plan utilization. West's balance sheet remains strong, with an increase in operating cash flow of $63 million compared to the same period last year. The company's full year 2020 net sales guidance is now in a range of between $2.1 billion and $2.11 billion, with an estimated organic sales growth of approximately 14% to 15%. West is expanding its HVP manufacturing capacity at existing sites to meet anticipated 2021 COVID-19 vaccine demand, with capex guidance remaining at $170 million to $180 million. The company received FDA clearance for its 20 millimeter Vial2Bag advanced product last evening. West remains focused on delivering value to all stakeholders and supporting the healthcare industry in resolving the global pandemic.